Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi, Bayer, Teva, Mitsubishi Tanabe Pharma, and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone914-847-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.71 billion
Profitability
Miscellaneous
Employees7,400
OptionableOptionable
Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions
What is Regeneron Pharmaceuticals' stock symbol?
Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."
How were Regeneron Pharmaceuticals' earnings last quarter?
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) released its earnings results on Wednesday, February, 6th. The biopharmaceutical company reported $6.84 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $5.10 by $1.74. The biopharmaceutical company earned $1.93 billion during the quarter, compared to analyst estimates of $1.73 billion. Regeneron Pharmaceuticals had a net margin of 36.43% and a return on equity of 29.77%. The company's revenue for the quarter was up 21.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.23 earnings per share. View Regeneron Pharmaceuticals' Earnings History.
When is Regeneron Pharmaceuticals' next earnings date?
What price target have analysts set for REGN?
21 Wall Street analysts have issued 1 year price targets for Regeneron Pharmaceuticals' shares. Their forecasts range from $305.00 to $483.00. On average, they anticipate Regeneron Pharmaceuticals' share price to reach $404.8750 in the next twelve months. This suggests that the stock has a possible downside of 3.8%. View Analyst Price Targets for Regeneron Pharmaceuticals.
What is the consensus analysts' recommendation for Regeneron Pharmaceuticals?
21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 13 hold ratings, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Regeneron Pharmaceuticals.
What are Wall Street analysts saying about Regeneron Pharmaceuticals stock?
Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Regeneron’s fourth-quarter results were impressive as the company comfortably beat on both the top and the bottom line. Regeneron’s growth driver, Eylea continues to drive sales, and label expansion of the drug into additional indications has further boosted growth. Dupixent too has boosted performance. The company is working to expand Dupixent’s label further in several other indications. This should diversify the company’s revenue base and reduce dependence on Eylea. In September 2018, the FDA approved its immuno-oncology therapy, Libtayo for the treatment of patients with metastatic or locally advanced CSCC who are not candidates for curative surgery or curative radiation. New drug approvals boost growth prospects of the company. Shares have outperformed the industry in the past six months. However, the company is highly dependent on Eylea for growth." (2/8/2019)
- 2. Cantor Fitzgerald analysts commented, "We see potential for the pipeline long-term, but from a stock perspective we see more headwinds than tailwinds over the next 12 months for the base business. We think that concerns around competition will continue to be an overhang over 2019 with late-stage readouts in atopic dermatitis. Although we see some potential near-term catalysts with asthma and nasal polyps, we would like to see the hematology and oncology pipeline story emerge a bit more. Valuation Summary We have a 12-month price target of $415 on REGN shares." (2/6/2019)
- 3. JPMorgan Chase & Co. analysts commented, "REGN today reported in-line 3Q product sales (total rev +$21M; 1%) and a bottom-line beat (+$0.74; 14%) while tightening and lowering OpEx/tax guidance. The 3Q print/call was rather uneventful albeit high on details; Eylea was generally in line with expectations (+7% YoY), and Dupixent/Praluent/Kevzara numbers were known following SNY’s print last Wednesday. With many (not all) 4Q18 clinical/regulatory catalysts in the rear view mirror, we expect investors to focus on ongoing product launches and the robustness of the Eylea franchise. Maintain Neutral." (11/7/2018)
Has Regeneron Pharmaceuticals been receiving favorable news coverage?
Media stories about REGN stock have trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Regeneron Pharmaceuticals earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are some of Regeneron Pharmaceuticals' key competitors?
Some companies that are related to Regeneron Pharmaceuticals include Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), AbbVie (ABBV), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Allergan (AGN), Zoetis (ZTS) and Takeda Pharmaceutical (TKPYY).
Who are Regeneron Pharmaceuticals' key executives?
Regeneron Pharmaceuticals' management team includes the folowing people:
- Dr. Leonard S. Schleifer, Co-Founder, Pres, CEO & Exec. Director (Age 66)
- Dr. George D. Yancopoulos, Founding Scientist, Pres, Chief Scientific Officer & Director (Age 59)
- Mr. Robert E. Landry Jr., Exec. VP of Fin. & CFO (Age 55)
- Dr. Neil Stahl, Exec. VP of R&D (Age 62)
- Mr. Daniel P. Van Plew, Exec. VP and Gen. Mang. of Industrial Operations & Product Supply (Age 46)
Who are Regeneron Pharmaceuticals' major shareholders?
Regeneron Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.48%), Harris Associates L P (2.78%), Polen Capital Management LLC (1.37%), Geode Capital Management LLC (1.00%), Northern Trust Corp (0.88%) and Sustainable Growth Advisers LP (0.86%). Company insiders that own Regeneron Pharmaceuticals stock include Charles A Baker, Christopher R Fenimore, George L Sing, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry, Robert J Terifay and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.
Which institutional investors are selling Regeneron Pharmaceuticals stock?
REGN stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Harris Associates L P, BB Biotech AG, Millennium Management LLC, Assenagon Asset Management S.A., Sustainable Growth Advisers LP, Manning & Napier Group LLC and Two Sigma Advisers LP. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Christopher R Fenimore, George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos and Sanofi. View Insider Buying and Selling for Regeneron Pharmaceuticals.
Which institutional investors are buying Regeneron Pharmaceuticals stock?
REGN stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Amundi Pioneer Asset Management Inc., BlackRock Inc., Mirae Asset Global Investments Co. Ltd., DSM Capital Partners LLC, Canada Pension Plan Investment Board, Mcdonald Capital Investors Inc. CA and MERIAN GLOBAL INVESTORS UK Ltd. View Insider Buying and Selling for Regeneron Pharmaceuticals.
How do I buy shares of Regeneron Pharmaceuticals?
Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Regeneron Pharmaceuticals' stock price today?
One share of REGN stock can currently be purchased for approximately $420.92.
How big of a company is Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals has a market capitalization of $45.55 billion and generates $6.71 billion in revenue each year. The biopharmaceutical company earns $2.44 billion in net income (profit) each year or $19.80 on an earnings per share basis. Regeneron Pharmaceuticals employs 7,400 workers across the globe.
What is Regeneron Pharmaceuticals' official website?
How can I contact Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]
MarketBeat Community Rating for Regeneron Pharmaceuticals (NASDAQ REGN)
MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote "Outperform" if you believe REGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
